Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Takeda Pharmaceutical leads the 33 pharmaceutical companies ranked by P/E ratio, at 304, ahead of Merck & Co (139) and Ligand Pharmaceuticals (120). Figures as of 18 Nov 2026, 20:50 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- First
- Takeda Pharmaceutical304
- Median
- 40.0
- Combined market value
- TRY 255.26T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Takeda PharmaceuticalTAK · Health Care | 304 | TRY 3.42T | TRY 1,071.38 | 1.83% down | 54% up | ||
| 2 | Merck & CoMRK · Health Care | 139 | TRY 17.12T | TRY 6,945.67 | 3.93% down | 51% up | ||
| 3 | Ligand PharmaceuticalsLGND · Health Care | 120 | TRY 301.4B | TRY 15,066.35 | 1.68% up | 43% up | ||
| 4 | TG TherapeuticsTGTX · Health Care | 98.5 | TRY 503.1B | TRY 3,328.35 | 5.25% up | 107% up | ||
| 5 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.1 | TRY 2.48T | TRY 2,127.62 | 1.01% down | 74% up | ||
| 6 | Jazz PharmaceuticalsJAZZ · Health Care | 72.9 | TRY 797.2B | TRY 12,420.31 | 2.32% up | 37% up | ||
| 7 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 71.8 | TRY 375.7B | TRY 4,781.23 | 0.32% down | 126% up | ||
| 8 | Amneal PharmaceuticalsAMRX · Health Care | 54.6 | TRY 383.6B | TRY 1,100.88 | 3.36% up | 83% up | ||
| 9 | BeOne MedicinesONC · Health Care | 51.7 | TRY 2.32T | TRY 20,331.20 | 2.44% down | 17% up | ||
| 10 | Corcept TherapeuticsCORT · Health Care | 51.0 | TRY 374.3B | TRY 3,420.14 | 3.21% down | 8% down | ||
| 11 | AbbVieABBV · Health Care | 49.1 | TRY 25.48T | TRY 14,415.05 | 2.38% down | 26% up | ||
| 12 | Eli LillyLLY · Health Care | 44.9 | TRY 62.16T | TRY 69,787.00 | 2.24% down | 35% up | ||
| 13 | Royalty PharmaRPRX · Health Care | 44.9 | TRY 1.99T | TRY 3,461.49 | 0.06% down | 78% up | ||
| 14 | GenmabGMAB · Health Care | 43.7 | TRY 1.59T | TRY 2,576.95 | 1.66% down | 70% up | ||
| 15 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.6 | TRY 629.8B | TRY 755.44 | 1.28% up | 5% up | ||
| 16 | Johnson & JohnsonJNJ · Health Care | 41.4 | TRY 33.16T | TRY 13,773.33 | 2.00% down | 38% up | ||
| 17 | PfizerPFE · Health Care | 40.0 | TRY 8.06T | TRY 1,413.54 | 1.55% down | 14% up | ||
| 18 | Abbott LaboratoriesABT · Health Care | 39.1 | TRY 9.14T | TRY 5,278.97 | 0.03% down | 17% down | ||
| 19 | Vertex PharmaceuticalsVRTX · Health Care | 34.6 | TRY 6.88T | TRY 27,120.03 | 0.67% up | 27% up | ||
| 20 | NovartisNVS · Health Care | 29.6 | TRY 14.79T | TRY 7,833.23 | 2.39% down | 25% up | ||
| 21 | Protagonist TherapeuticsPTGX · Health Care | 26.8 | TRY 417.1B | TRY 6,390.94 | 1.65% up | 46% up | ||
| 22 | AstraZenecaAZN · Health Care | 25.3 | TRY 13.98T | TRY 9,016.81 | 1.90% down | 2% up | ||
| 23 | SanofiSNY · Health Care | 23.5 | TRY 5.71T | TRY 2,378.01 | 0.79% down | 4% down | ||
| 24 | United TherapeuticsUTHR · Health Care | 21.9 | TRY 1.24T | TRY 29,190.67 | 0.90% down | 23% up | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 20.9 | TRY 4.93T | TRY 47,687.24 | 1.27% down | 36% up | ||
| 26 | Ascendis PharmaASND · Health Care | 17.8 | TRY 893.4B | TRY 13,620.53 | 0.41% down | 28% up | ||
| 27 | GSKGSK · Health Care | 16.9 | TRY 4.92T | TRY 2,452.90 | 1.22% down | 6% up | ||
| 28 | ZoetisZTS · Health Care | 14.6 | TRY 1.75T | TRY 4,317.28 | 2.55% up | 29% down | ||
| 29 | Bristol-Myers SquibbBMY · Health Care | 13.2 | TRY 6.14T | TRY 3,005.98 | 2.84% down | 34% up | ||
| 30 | GrifolsGRFS · Health Care | 10.2 | TRY 290.5B | TRY 426.89 | 1.91% down | 1% up | ||
| 31 | Novo NordiskNVO · Health Care | 10.0 | TRY 8.77T | TRY 1,990.71 | 3.01% down | 17% down | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | TRY 1.01T | TRY 7,533.93 | 4.54% down | 66% down | ||
| 33 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | TRY 228.8B | TRY 2,090.05 | 1.42% down | 88% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 50.4296 TRY). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/E ratio?
Takeda Pharmaceutical (304), Merck & Co (139) and Ligand Pharmaceuticals (120) are the top three of the 33 pharmaceutical companies ranked by P/E ratio as of 18 Nov 2026, 20:50 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of TRY 255.26T as of 18 Nov 2026, 20:50 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.